| Metric | Value (₹ Cr) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 130.22 | 4.4% | 37.0% |
| Total Income | 135.66 | 6.5% | 38.5% |
| Expenditure | 111.57 | 4.6% | 29.6% |
| PBT | 24.08 | 14.3% | 103.7% |
| Net Profit | 18.03 | 16.5% | 62.1% |
| OPM | 20.45% | 0.27pp | 21.39pp |
| NPM | 13.29% | 1.60pp | 1.93pp |
| EPS | 6.48 | 13.5% | 64.5% |
Fermenta Biotech's H1FY26 Consolidated Revenues Surge 57%, Net Profit Soars 664% YoY
11 Nov 2025 · 11 Nov 2025, 05:37 pm
Summary
Fermenta Biotech Limited, a leading manufacturer of premium-grade APIs, intermediates, and mixes of vitamins and minerals, announced its financial results for H1FY26. The company's consolidated revenue (other than from real estate) was INR 275.2 crore, up 59% from the same year-ago period. EBITDA for the same period was INR 67.2 crore, up 155%. The human nutrition segment volumes grew 74% over H1FY25, and the animal nutrition segment volumes grew 6% with a 35% increase in average realization.
Key Highlights
- 1
Consolidated Revenues for H1FY26: INR 280.7 crore, up by INR 101.8 crore YoY
- 2
Consolidated EBITDA for H1FY26: INR 69.1 crore, up 173% YoY
- 3
Q2FY26 Consolidated Revenues: INR 135.7 crore, up 39% YoY; down 6% QoQ
- 4
Human nutrition segment volumes grew 74% over H1FY25
- 5
Animal nutrition segment volumes grew 6% and average realization rose 35% over H1IFY25
- 6
Other Income includes non-recurring insurance claim received amounting to INR 2.7 crore in QIFY26 and H1FY26
- 7
German toll manufacturing subsidiary's HIFY26 revenue: INR 34.3 crores, up 194% YoY
- 8
US trading business subsidiary's HIFY26 revenue: INR 30.3 crore, up 68% from a year ago
Management Comments
Prashant Nagre
Managing Director
The turnaround of FY25 was further confirmed in H1FY26. While core revenue growth, excluding that from real estate unlocking, in FY25 over FY24 was 57%, H1FY26 excluding that from real estate unlocking, the revenue was already 64.5% of that achieved in full FY25. EBITDA in H1FY26, excluding real estate, was 81% of the total EBITDA for FY25. The process patent for the production of completely vegan and vegetarian-friendly Vitamin D3 will help Fermenta capture emerging global opportunities across nutraceuticals and food fortification sectors, where sustainable, plant-derived ingredients command premiums and growing market share. The transfer of our environmental solutions portfolio to a dedicated subsidiary creates a focused entity that can target accelerated growth in this critical sector.
Informational and educational content only. Not investment advice.